BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-21. [PMID: 21531810 DOI: 10.1158/1078-0432.CCR-10-3408] [Cited by in Crossref: 269] [Cited by in F6Publishing: 179] [Article Influence: 24.5] [Reference Citation Analysis]
Number Citing Articles
1 Namba K, Tomida S, Matsubara T, Takahashi Y, Kurihara E, Ogoshi Y, Yoshioka T, Takeda T, Torigoe H, Sato H, Shien K, Yamamoto H, Soh J, Tsukuda K, Toyooka S. Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma. BMC Cancer 2019;19:175. [PMID: 30808329 DOI: 10.1186/s12885-019-5374-1] [Reference Citation Analysis]
2 Falla-Martinez JC, Espinosa D, Baena JC, Rodriguez LX, Sua LF, Zambrano AR. An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report. J Med Case Rep 2019;13:144. [PMID: 31088573 DOI: 10.1186/s13256-019-2075-y] [Reference Citation Analysis]
3 Nasu S, Shiroyama T, Morita S, Takata S, Takada H, Masuhiro K, Tanaka A, Morishita N, Suzuki H, Okamoto N, Hirashima T. Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations. Intern Med 2018;57:3643-5. [PMID: 30146570 DOI: 10.2169/internalmedicine.0923-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
4 Cheng YW, Stefaniuk C, Jakubowski MA. Real-time PCR and targeted next-generation sequencing in the detection of low level EGFR mutations: Instructive case analyses. Respir Med Case Rep 2019;28:100901. [PMID: 31367517 DOI: 10.1016/j.rmcr.2019.100901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Oxnard GR, Miller VA, Robson ME, Azzoli CG, Pao W, Ladanyi M, Arcila ME. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 2012;7:1049-52. [PMID: 22588155 DOI: 10.1097/JTO.0b013e318250ed9d] [Cited by in Crossref: 73] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
6 Güler Tezel G, Şener E, Aydın Ç, Önder S. Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population. Balkan Med J 2017;34:567-71. [PMID: 28832323 DOI: 10.4274/balkanmedj.2017.0297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Ulmer B, Odenthal M, Buettner R, Roth W, Kloth M. Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. NPJ Syst Biol Appl 2022;8:2. [PMID: 35046405 DOI: 10.1038/s41540-021-00211-8] [Reference Citation Analysis]
8 Attili I, Passaro A, Pisapia P, Malapelle U, de Marinis F. Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence. Current Oncology 2022;29:255-66. [DOI: 10.3390/curroncol29010024] [Reference Citation Analysis]
9 Wang X, Zhong D. [Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation]. Zhongguo Fei Ai Za Zhi 2019;22:324-8. [PMID: 31109443 DOI: 10.3779/j.issn.1009-3419.2019.05.10] [Reference Citation Analysis]
10 Kaderbhai CG, Boidot R, Beltjens F, Chevrier S, Arnould L, Favier L, Lagrange A, Coudert B, Ghiringhelli F. Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer. Oncotarget 2016;7:24860-70. [PMID: 27027238 DOI: 10.18632/oncotarget.8391] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
11 Prabhash K. Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update. South Asian J Cancer 2019;8:1-17. [PMID: 30766843 DOI: 10.4103/sajc.sajc_227_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Wang J, Wang B, Chu H, Yao Y. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther 2016;9:3711-26. [PMID: 27382309 DOI: 10.2147/OTT.S106399] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
13 Garinet S, Laurent-Puig P, Blons H, Oudart JB. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies? J Clin Med. 2018;7. [PMID: 29890761 DOI: 10.3390/jcm7060144] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
14 He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, Ginsberg MS, Zhao B, Kris MG, Eck MJ, Jänne PA, Ladanyi M, Oxnard GR. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res. 2012;18:1790-1797. [PMID: 22190593 DOI: 10.1158/1078-0432.ccr-11-2361.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov 2021;11:1688-99. [PMID: 33632775 DOI: 10.1158/2159-8290.CD-20-1598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
16 Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 2019;24:731-70. [PMID: 31049758 DOI: 10.1007/s10147-019-01431-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
17 Peng L, Song ZG, Jiao SC. Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations. Sci Rep 2014;4:6104. [PMID: 25130612 DOI: 10.1038/srep06104] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
18 Saxon JA, Sholl LM, Jänne PA. EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. J Thorac Oncol 2017;12:884-9. [PMID: 28088511 DOI: 10.1016/j.jtho.2017.01.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
19 Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 2017;8:114371-92. [PMID: 29371993 DOI: 10.18632/oncotarget.22825] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 10.2] [Reference Citation Analysis]
20 Landi L, Cappuzzo F. Irreversible EGFR-TKIs: dreaming perfection. Transl Lung Cancer Res. 2013;2:40-49. [PMID: 25806203 DOI: 10.3978/j.issn.2218-6751.2012.12.05] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
21 Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 2014;25:423-8. [PMID: 24478319 DOI: 10.1093/annonc/mdt573] [Cited by in Crossref: 118] [Cited by in F6Publishing: 125] [Article Influence: 16.9] [Reference Citation Analysis]
22 Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol 2020;61:167-79. [PMID: 31562956 DOI: 10.1016/j.semcancer.2019.09.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 13.3] [Reference Citation Analysis]
23 Li X, Zhou C. Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. Oncotarget 2017;8:100801-18. [PMID: 29246024 DOI: 10.18632/oncotarget.19007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
24 Leventakos K, Kipp BR, Rumilla KM, Winters JL, Yi ES, Mansfield AS. S768I Mutation in EGFR in Patients with Lung Cancer. J Thorac Oncol 2016;11:1798-801. [PMID: 27211795 DOI: 10.1016/j.jtho.2016.05.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
25 Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).J Clin Oncol. 2020;38:488-495. [PMID: 31825714 DOI: 10.1200/JCO.19.00931] [Cited by in Crossref: 73] [Cited by in F6Publishing: 44] [Article Influence: 24.3] [Reference Citation Analysis]
26 Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN. Standardizing biomarker testing for Canadian patients with advanced lung cancer. Curr Oncol 2018;25:73-82. [PMID: 29507487 DOI: 10.3747/co.25.3867] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhang X, Jiang Y, Yu H, Xia H, Wang X. A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients. World J Surg Oncol 2020;18:172. [PMID: 32677962 DOI: 10.1186/s12957-020-01947-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res 2012;1:5-13. [PMID: 25806150 DOI: 10.3978/j.issn.2218-6751.2011.12.01] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
29 Yang Y, Meng Y, Zhang H, Shen X, Li R, Yu L, Liu B, Wang L. Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma. Oncol Lett 2018;15:3295-304. [PMID: 29467863 DOI: 10.3892/ol.2017.7652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
30 Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci 2016;107:1179-86. [PMID: 27323238 DOI: 10.1111/cas.12996] [Cited by in Crossref: 152] [Cited by in F6Publishing: 151] [Article Influence: 25.3] [Reference Citation Analysis]
31 Yang X, Chen H, Zhang H, Duan J, An T, Zhao J, Zhuo M, Wu M, Wang J. [Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor 
Receptor Mutations in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2015;18:493-9. [PMID: 26302346 DOI: 10.3779/j.issn.1009-3419.2015.08.04] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
32 Ackerman A, Goldstein MA, Kobayashi S, Costa DB. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. J Thorac Oncol 2012;7:e19-20. [PMID: 22982663 DOI: 10.1097/JTO.0b013e3182635ab4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
33 Chen YH, Chen YF, Chen CY, Shih JY, Yu CJ. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. BMC Cancer 2019;19:1006. [PMID: 31655564 DOI: 10.1186/s12885-019-6140-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
34 Andreis TF, Correa BS, Vianna FS, De-Paris F, Siebert M, Leistner-Segal S, Hahn EC, Ulbrich JM, Rivero LFR, De Oliveira FH, Lorandi V, Ashton-Prolla P, Macedo GS. Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country. J Glob Oncol 2019;5:1-9. [PMID: 31532708 DOI: 10.1200/JGO.19.00174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
35 Lin A, Wei T, Meng H, Luo P, Zhang J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer 2019;18:139. [PMID: 31526368 DOI: 10.1186/s12943-019-1062-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 14.7] [Reference Citation Analysis]
36 Vu TH, Nguyen HTT, Dao LK, Duong CK, Nguyen CV, Doan TT, Nguyen HTT, Hoang HH, Dinh DK, Le GV, Vu TT, Truong MC, Nguyen LT. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Asian Pac J Cancer Prev 2021;22:1581-90. [PMID: 34048189 DOI: 10.31557/APJCP.2021.22.5.1581] [Reference Citation Analysis]
37 Santis G, Angell R, Nickless G, Quinn A, Herbert A, Cane P, Spicer J, Breen R, McLean E, Tobal K. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS One 2011;6:e25191. [PMID: 21949883 DOI: 10.1371/journal.pone.0025191] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
38 Li WY, Zhao TT, Xu HM, Wang ZN, Xu YY, Han Y, Song YX, Wu JH, Xu H, Yin SC, Liu XY, Miao ZF. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer 2019;19:145. [PMID: 30760227 DOI: 10.1186/s12885-019-5331-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
39 Domingues PM, Montella T, Baldotto C. Rare versus Artifactual EGFR Mutations. Journal of Thoracic Oncology 2015;10:e79-80. [DOI: 10.1097/jto.0000000000000590] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Brindel A, Althakfi W, Barritault M, Watkin E, Maury JM, Bringuier PP, Girard N, Brevet M. Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors. J Thorac Dis 2020;12:4643-50. [PMID: 33145037 DOI: 10.21037/jtd-19-3790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Onishi I, Kirimura S, Wakejima R, Okubo K, Odai T, Kakuta R, Kano Y, Ikeda S, Akashi T, Kitagawa M. Primary pulmonary choriocarcinoma with a genomic sequence. Pathol Int 2021. [PMID: 34904768 DOI: 10.1111/pin.13193] [Reference Citation Analysis]
42 Pareja F, Geyer FC, Kumar R, Selenica P, Piscuoglio S, Ng CKY, Burke KA, Edelweiss M, Murray MP, Brogi E, Weigelt B, Reis-Filho JS. Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. NPJ Breast Cancer 2017;3:40. [PMID: 29043292 DOI: 10.1038/s41523-017-0042-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
43 Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013;5:216ra177. [PMID: 24353160 DOI: 10.1126/scitranslmed.3007205] [Cited by in Crossref: 258] [Cited by in F6Publishing: 242] [Article Influence: 32.3] [Reference Citation Analysis]
44 Khan NA, Mirshahidi S, Mirshahidi HR. A novel insertion mutation on exon 20 of epidermal growth factor receptor, conferring resistance to erlotinib. Case Rep Oncol 2014;7:491-6. [PMID: 25202264 DOI: 10.1159/000365325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
45 Markóczy Z, Sárosi V, Kudaba I, Gálffy G, Turay ÜY, Demirkazik A, Purkalne G, Somfay A, Pápai-Székely Z, Rásó E, Ostoros G. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial. BMC Cancer 2018;18:598. [PMID: 29801465 DOI: 10.1186/s12885-018-4283-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
46 Sumi T, Kamada K, Shijubou N, Yamada Y, Nakata H, Mori Y, Chiba H. Long-term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review. Respirol Case Rep 2021;9:e00759. [PMID: 33976888 DOI: 10.1002/rcr2.759] [Reference Citation Analysis]
47 Wu SG, Chang YL, Lin JW, Wu CT, Chen HY, Tsai MF, Lee YC, Yu CJ, Shih JY. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One 2011;6:e23303. [PMID: 21858063 DOI: 10.1371/journal.pone.0023303] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
48 Watanabe M, Kawaguchi T, Isa SI, Ando M, Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, Kawashima O, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Watanabe K, Matsumura A, Koh Y. Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR. EBioMedicine 2017;21:86-93. [PMID: 28625519 DOI: 10.1016/j.ebiom.2017.06.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
49 Sehgal K, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist 2021;26:281-7. [PMID: 32969527 DOI: 10.1002/onco.13537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335 [PMID: 33644199 DOI: 10.12998/wjcc.v9.i6.1329] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
51 Sun Z, Shi Y, Shen Y, Cao L, Zhang W, Guan X. Analysis of different HER-2 mutations in breast cancer progression and drug resistance. J Cell Mol Med 2015;19:2691-701. [PMID: 26305917 DOI: 10.1111/jcmm.12662] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
52 Li L, Zhang Z, Bie Z, Wang Z, Zhang P, Nie X, Li Y, Wang H, Ai B, Cheng G. Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients. Chin J Cancer Res 2015;27:294-300. [PMID: 26157326 DOI: 10.3978/j.issn.1000-9604.2015.05.03] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
53 Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013;31:1070-80. [PMID: 23401451 DOI: 10.1200/JCO.2012.43.3912] [Cited by in Crossref: 297] [Cited by in F6Publishing: 184] [Article Influence: 33.0] [Reference Citation Analysis]
54 Er P, Zhang T, Wang J, Pang Q, Wang P. Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review. Cancer Biol Med 2017;14:418-25. [PMID: 29372109 DOI: 10.20892/j.issn.2095-3941.2017.0079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Kerner GS, Schuuring E, Sietsma J, Hiltermann TJ, Pieterman RM, de Leede GP, van Putten JW, Liesker J, Renkema TE, van Hengel P, Platteel I, Timens W, Groen HJ; CTMM Air Force Consortium. Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome. PLoS One 2013;8:e70346. [PMID: 23922984 DOI: 10.1371/journal.pone.0070346] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
56 Chang GC, Lam DC, Tsai CM, Chen YM, Shih JY, Aggarwal S, Wang S, Kim SW, Kim YC, Wahid I, Li R, Lim DW, Sriuranpong V, Chan RT, Lorence RM, Carriere P, Raabe C, Cseh A, Park K. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. Int J Clin Oncol 2021;26:841-50. [PMID: 33783657 DOI: 10.1007/s10147-021-01869-0] [Reference Citation Analysis]
57 Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019;8:302-16. [PMID: 31367543 DOI: 10.21037/tlcr.2019.04.12] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
58 Spagnuolo A, Muto M, Monaco F, Colantuoni G, Gridelli C. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. Transl Lung Cancer Res 2019;8:1134-51. [PMID: 32010591 DOI: 10.21037/tlcr.2019.12.24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Wang S, Li J. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. Onco Targets Ther 2019;12:6535-48. [PMID: 31496745 DOI: 10.2147/OTT.S198945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
60 Zhang B, Shi C, Gao Z, Zhong H, Xiong L, Gu A, Wang W, Chu T, Zhang W, Wang H, Zhang X, Zhong R, Han B. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study). BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09409-3] [Reference Citation Analysis]
61 Miller ML, Reznik E, Gauthier NP, Aksoy BA, Korkut A, Gao J, Ciriello G, Schultz N, Sander C. Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. Cell Syst 2015;1:197-209. [PMID: 27135912 DOI: 10.1016/j.cels.2015.08.014] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 10.4] [Reference Citation Analysis]
62 Lin R, Chen R, Chen Z, Hu L, Guo W, Zhang Z, Lin L, Chen H. Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review. Front Oncol 2021;11:731572. [PMID: 34540698 DOI: 10.3389/fonc.2021.731572] [Reference Citation Analysis]
63 Macedo JE. New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer. World J Respirol 2016; 6(2): 57-62 [DOI: 10.5320/wjr.v6.i2.57] [Reference Citation Analysis]
64 Kim P, Li H, Wang J, Zhao Z. Landscape of drug-resistance mutations in kinase regulatory hotspots. Brief Bioinform 2021;22:bbaa108. [PMID: 32510566 DOI: 10.1093/bib/bbaa108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
65 An N, Wang H, Zhu H, Yan W, Jing W, Kong L, Zhang Y, Yu J. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report. Onco Targets Ther 2019;12:7399-404. [PMID: 31686847 DOI: 10.2147/OTT.S221638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Mathew B, Takekoshi D, Sammani S, Epshtein Y, Sharma R, Smith BD, Mitra S, Desai AA, Weichselbaum RR, Garcia JG, Jacobson JR. Role of GADD45a in murine models of radiation- and bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2015;309:L1420-9. [PMID: 26498248 DOI: 10.1152/ajplung.00146.2014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
67 Persky NS, Hernandez D, Do Carmo M, Brenan L, Cohen O, Kitajima S, Nayar U, Walker A, Pantel S, Lee Y, Cordova J, Sathappa M, Zhu C, Hayes TK, Ram P, Pancholi P, Mikkelsen TS, Barbie DA, Yang X, Haq R, Piccioni F, Root DE, Johannessen CM. Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nat Struct Mol Biol 2020;27:92-104. [PMID: 31925410 DOI: 10.1038/s41594-019-0358-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
68 Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, Morinaga R, Wataya H, Fujii A, Nakagaki N, Tsuruta N, Takeshita M, Iwama E, Harada T, Nakanishi Y, Okamoto I. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget 2017;8:68123-30. [PMID: 28978102 DOI: 10.18632/oncotarget.19243] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
69 Yeh P, Chen H, Andrews J, Naser R, Pao W, Horn L. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res 2013;19:1894-901. [PMID: 23344264 DOI: 10.1158/1078-0432.CCR-12-1894] [Cited by in Crossref: 75] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
70 Zhang T, Wang J, Su Y, Chen X, Yan Q, Li Q, Sun L, Wang Y, Er P, Pang Q, Wang P. Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation? Oncotarget 2017;8:40594-605. [PMID: 28380449 DOI: 10.18632/oncotarget.16505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Liu HL, Han G, Peng M, Weng YM, Yuan JP, Yang GF, Yu JM, Song QB. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. J Huazhong Univ Sci Technolog Med Sci 2017;37:864-72. [PMID: 29270745 DOI: 10.1007/s11596-017-1819-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Cheng C, Wang R, Li Y, Pan Y, Zhang Y, Li H, Zheng D, Zheng S, Shen X, Sun Y, Chen H. EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis. Sci Rep 2015;5:13959. [PMID: 26354324 DOI: 10.1038/srep13959] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
73 Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol 2022:S1044-579X(22)00096-7. [PMID: 35427766 DOI: 10.1016/j.semcancer.2022.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Martínez-Jiménez F, Overington JP, Al-Lazikani B, Marti-Renom MA. Rational design of non-resistant targeted cancer therapies. Sci Rep 2017;7:46632. [PMID: 28436422 DOI: 10.1038/srep46632] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
75 Takamochi K, Oh S, Suzuki K. Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. Oncol Lett 2013;6:1207-12. [PMID: 24179496 DOI: 10.3892/ol.2013.1551] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
76 Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors. Oncologist 2016;21:156-64. [PMID: 26768482 DOI: 10.1634/theoncologist.2015-0288] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
77 Zheng Z, Jin X, Lin B, Su H, Chen H, Fei S, Zhao L, Deng X, Xie D, Xie C. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations. J Cancer 2017;8:597-605. [PMID: 28367239 DOI: 10.7150/jca.16959] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
78 Francis G, Stein S. Circulating Cell-Free Tumour DNA in the Management of Cancer. Int J Mol Sci 2015;16:14122-42. [PMID: 26101870 DOI: 10.3390/ijms160614122] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 9.0] [Reference Citation Analysis]
79 Ke EE, Wu YL. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. Ther Adv Respir Dis. 2016;10:256-264. [PMID: 26929305 DOI: 10.1177/1753465816634545] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
80 Wu SG, Yu CJ, Yang JC, Shih JY. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation.Ther Adv Med Oncol. 2020;12:1758835920946156. [PMID: 32843903 DOI: 10.1177/1758835920946156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Woo HS, Ahn HK, Lee HY, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Invest New Drugs 2014;32:1311-5. [PMID: 25146938 DOI: 10.1007/s10637-014-0146-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
82 Zhou Y, Yang Y, Yang C, Chen Y, Yang C, Du Y, Zhao G, Guo Y, Ye L, Huang Y. Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China. Oncotarget 2017;8:15023-33. [PMID: 28107191 DOI: 10.18632/oncotarget.14706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
83 Chang YS, Choi CM, Lee JC. Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma. Tuberc Respir Dis (Seoul) 2016;79:248-56. [PMID: 27790276 DOI: 10.4046/trd.2016.79.4.248] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
84 Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E, Fumagalli C, Pisapia P, Pepe F, De Luca C, Cucchiara F, Troncone G, Danesi R, Spaggiari L, De Marinis F, Rolfo C. Understanding EGFR heterogeneity in lung cancer. ESMO Open 2020;5:e000919. [PMID: 33067323 DOI: 10.1136/esmoopen-2020-000919] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
85 Kuan FC, Li SH, Wang CL, Lin MH, Tsai YH, Yang CT. Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. Oncotarget 2017;8:1343-53. [PMID: 27935868 DOI: 10.18632/oncotarget.13815] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
86 Cheng X, Chen H. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther 2014;7:1689-704. [PMID: 25285017 DOI: 10.2147/OTT.S66502] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
87 Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 2014;25:126-31. [PMID: 24285021 DOI: 10.1093/annonc/mdt418] [Cited by in Crossref: 156] [Cited by in F6Publishing: 164] [Article Influence: 17.3] [Reference Citation Analysis]
88 Mountzios G, Koumarianou A, Bokas A, Mavroudis D, Samantas E, Fergadis EG, Linardou H, Katsaounis P, Athanasiadis E, Karamouzis MV, Pentheroudakis G, Lampaki S, Froudarakis ME, Perdikouri EA, Somarakis A, Papageorgiou F, Paparepa Z, Nikolaou A, Syrigos KN. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study. Cancers (Basel) 2021;13:3172. [PMID: 34202063 DOI: 10.3390/cancers13133172] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Li K, Yang M, Liang N, Li S. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). Oncol Rep 2017;37:1347-58. [PMID: 28184913 DOI: 10.3892/or.2017.5409] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
90 Lettig L, Sahnane N, Pepe F, Cerutti R, Albeni C, Franzi F, Veronesi G, Ogliari F, Pastore A, Tuzi A, Pinotti G, Bovio A, Verusio C, Giordano M, Troncone G, Sessa F, Malapelle U, Furlan D. EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing. Transl Lung Cancer Res 2019;8:584-92. [PMID: 31737495 DOI: 10.21037/tlcr.2019.09.18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
91 Wu SG, Chang YL, Yu CJ, Yang PC, Shih JY. Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Res 2017;3:00092-2016. [PMID: 28717642 DOI: 10.1183/23120541.00092-2016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
92 Page RD, Drusbosky LM, Dada H, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA, Leighl NB. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer 2021:S1525-7304(21)00262-X. [PMID: 34782240 DOI: 10.1016/j.cllc.2021.10.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Kate S, Chougule A, Joshi A, Noronha V, Patil V, Dusane R, Solanki L, Tiwrekar P, Trivedi V, Prabhash K. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer (Auckl) 2019;10:1-10. [PMID: 30774491 DOI: 10.2147/LCTT.S181406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
94 Sakai A, Tagami M, Kakehashi A, Katsuyama-Yoshikawa A, Misawa N, Wanibuchi H, Azumi A, Honda S. Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment. PLoS One 2020;15:e0238120. [PMID: 32833992 DOI: 10.1371/journal.pone.0238120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
95 Ullas B, Shrinidhi N, Mansi S, Narayan S, Parveen J, Surender D, Joslia JT, Anurag M. All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations. J Cancer Res Clin Oncol 2022. [PMID: 35581383 DOI: 10.1007/s00432-022-04033-x] [Reference Citation Analysis]
96 Lei L, Wang WX, Zhu YC, Li JL, Fang Y, Wang H, Zhuang W, Zhang YB, Wang LP, Fang MY, Xu CW, Wang XJ, Lv TF, Song Y. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study. Cancer Med 2020;9:12-8. [PMID: 31692291 DOI: 10.1002/cam4.2652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
97 Rossi S, D'Argento E, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Martini M, Cassano A, Barone C. Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. Mol Diagn Ther 2016;20:55-63. [PMID: 26645830 DOI: 10.1007/s40291-015-0176-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
98 Gao X, Zhao Y, Bao Y, Yin W, Liu L, Liu R, Yu Z, Zhou X, Shuai J. Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer. Cancer Manag Res 2019;11:9621-30. [PMID: 32009817 DOI: 10.2147/CMAR.S216721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
99 Tseng JS, Yang TY, Chen KC, Hsu KH, Yu CJ, Liao WY, Tsai CR, Tsai MH, Yu SL, Su KY, Chen JJ, Chen HY, Chang GC. Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. Onco Targets Ther 2014;7:799-805. [PMID: 24920920 DOI: 10.2147/OTT.S62639] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
100 Wu SG, Chang YL, Yu CJ, Yang PC, Shih JY. The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. Sci Rep 2016;6:35249. [PMID: 27734950 DOI: 10.1038/srep35249] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
101 Chu QS. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. Ther Adv Med Oncol 2020;12:1758835919895756. [PMID: 32047535 DOI: 10.1177/1758835919895756] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
102 Sato H, Offin M, Kubota D, Yu HA, Wilhelm C, Toyooka S, Somwar R, Kris MG, Ladanyi M. Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers. J Thorac Oncol 2021;16:113-26. [PMID: 33038514 DOI: 10.1016/j.jtho.2020.09.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
103 Ricciuti B, Mecca C, Cenci M, Leonardi GC, Perrone L, Mencaroni C, Crinò L, Grignani F, Baglivo S, Chiari R, Sidoni A, Paglialunga L, Currà MF, Murano E, Minotti V, Metro G. miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance. Ecancermedicalscience 2015;9:569. [PMID: 26435742 DOI: 10.3332/ecancer.2015.569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
104 Mao L, Zhao W, Li X, Zhang S, Zhou C, Zhou D, Ou X, Xu Y, Tang Y, Ou X, Hu C, Ding X, Luo P, Yu S. Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory. Pathol Oncol Res 2021;27:602726. [PMID: 34257561 DOI: 10.3389/pore.2021.602726] [Reference Citation Analysis]
105 Majem M, Remon J. Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. Transl Lung Cancer Res 2013;2:226-37. [PMID: 25806236 DOI: 10.3978/j.issn.2218-6751.2013.03.09] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
106 Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res 2018;24:1038-47. [PMID: 29217530 DOI: 10.1158/1078-0432.CCR-17-2289] [Cited by in Crossref: 83] [Cited by in F6Publishing: 49] [Article Influence: 16.6] [Reference Citation Analysis]
107 Zeng Y, Guo T, Zhou Y, Zhao Y, Chu L, Chu X, Yang X, Ni J, Zhu Z. Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters. BMC Cancer 2022;22:198. [PMID: 35189835 DOI: 10.1186/s12885-022-09245-5] [Reference Citation Analysis]
108 Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol 2014;9:189-94. [PMID: 24419415 DOI: 10.1097/JTO.0000000000000048] [Cited by in Crossref: 108] [Cited by in F6Publishing: 71] [Article Influence: 13.5] [Reference Citation Analysis]
109 Simionato F, Calvetti L, Cosci M, Scarparo S, Aprile G. Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring EGFR G719A/V769M Complex Mutation. Onco Targets Ther 2020;13:12027-31. [PMID: 33262603 DOI: 10.2147/OTT.S280933] [Reference Citation Analysis]
110 Russo A, Franchina T, Ricciardi GR, Picone A, Ferraro G, Zanghì M, Toscano G, Giordano A, Adamo V. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget 2015;6:26814-25. [PMID: 26308162 DOI: 10.18632/oncotarget.4254] [Cited by in Crossref: 107] [Cited by in F6Publishing: 104] [Article Influence: 17.8] [Reference Citation Analysis]
111 Li L, Luo S, Lin H, Yang H, Chen H, Liao Z, Lin W, Zheng W, Xie X. Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer. J Thorac Dis 2017;9:2510-20. [PMID: 28932557 DOI: 10.21037/jtd.2017.07.57] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
112 Hu R, Xu H, Jia P, Zhao Z. KinaseMD: kinase mutations and drug response database. Nucleic Acids Res 2021;49:D552-61. [PMID: 33137204 DOI: 10.1093/nar/gkaa945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
113 Tan J, Hu C, Deng P, Wan R, Cao L, Li M, Yang H, Gu Q, An J, Jiang J. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations-The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations. Front Oncol 2021;11:646577. [PMID: 34513661 DOI: 10.3389/fonc.2021.646577] [Reference Citation Analysis]
114 He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, Ginsberg MS, Zhao B, Kris MG, Eck MJ, Jänne PA, Ladanyi M, Oxnard GR. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res 2012;18:1790-7. [PMID: 22190593 DOI: 10.1158/1078-0432.CCR-11-2361] [Cited by in Crossref: 104] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
115 Wu JY, Shih JY. Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer. Onco Targets Ther 2016;9:6137-45. [PMID: 27785061 DOI: 10.2147/OTT.S118071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
116 Tetrault SM, Rice JE, Wangh LJ, Sanchez JA. Single-Tube Mutation Scanning of The Epidermal Growth Factor Receptor Gene Using Multiplex LATE-PCR and Lights-On/Lights-Off Probes. J Mol Biomark Diagn 2014;5:1000175. [PMID: 25411647 DOI: 10.4172/2155-9929.1000175] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
117 Ding D, Yu Y, Li Z, Niu X, Lu S. The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis. Onco Targets Ther 2014;7:387-93. [PMID: 24623981 DOI: 10.2147/OTT.S58870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
118 Kobayashi H, Wakuda K, Takahashi T. Effectiveness of afatinib in lung cancer with paralytic ileus due to peritoneal carcinomatosis. Respirol Case Rep 2016;4:e00197. [PMID: 28031832 DOI: 10.1002/rcr2.197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
119 Kitadai R, Okuma Y. Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. Cancers 2022;14:2519. [DOI: 10.3390/cancers14102519] [Reference Citation Analysis]
120 Burnett H, Emich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLoS One 2021;16:e0247620. [PMID: 33684140 DOI: 10.1371/journal.pone.0247620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
121 Velazquez AI, McCoach CE. Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. J Thorac Dis 2020;12:2896-909. [PMID: 32642202 DOI: 10.21037/jtd.2019.08.31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Int J Mol Sci 2019;20:E1431. [PMID: 30901844 DOI: 10.3390/ijms20061431] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
123 Zhang Q, Cui Y, Zhang J, Kenjiabieke J, Aerxiding P. Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups. Exp Ther Med 2020;19:3513-20. [PMID: 32346412 DOI: 10.3892/etm.2020.8612] [Reference Citation Analysis]
124 Zhao ZR, Lin YB, Ng CSH, Zhang R, Wu X, Ou Q, Chen W, Zhou WJ, Lin YB, Su XD, Shao YW, Long H. Mutation Profile of Resected EGFR-Mutated Lung Adenocarcinoma by Next-Generation Sequencing. Oncologist 2019;24:1368-74. [PMID: 30872465 DOI: 10.1634/theoncologist.2018-0567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
125 Yu S, Zhang Y, Pan Y, Cheng C, Sun Y, Chen H. The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive. Onco Targets Ther 2017;10:4507-15. [PMID: 28979142 DOI: 10.2147/OTT.S131999] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
126 Liu Q, Yang Y, Fan X, Xin X, Pan Q, Zhang Y, Liu B, Wei J. Heterogeneity response to afatinib in gastric cancer patient with uncommon epidermal growth factor receptor (EGFR) mutations: a case report. Ann Transl Med 2021;9:814. [PMID: 34268427 DOI: 10.21037/atm-20-7312] [Reference Citation Analysis]
127 Kanazu M, Mori M, Kimura M, Nishino K, Shiroyama T, Nagatomo I, Ihara S, Komuta K, Suzuki H, Hirashima T, Kumagai T, Imamura F. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study. Thorac Cancer 2021;12:90-6. [PMID: 33124128 DOI: 10.1111/1759-7714.13718] [Reference Citation Analysis]
128 Xu F, Xia ML, Pan HY, Pan JW, Shen YH. Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report. World J Clin Cases 2022; 10(17): 5916-5922 [DOI: 10.12998/wjcc.v10.i17.5916] [Reference Citation Analysis]
129 Pinsolle J, McLeer-Florin A, Giaj Levra M, de Fraipont F, Emprou C, Gobbini E, Toffart AC. Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. Front Med (Lausanne) 2019;6:233. [PMID: 31737634 DOI: 10.3389/fmed.2019.00233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
130 Cao Y, Xu H, Liao M, Qu Y, Xu L, Zhu D, Wang B, Tian S. Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma. Int J Clin Oncol 2018;23:249-57. [PMID: 28988295 DOI: 10.1007/s10147-017-1197-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
131 Roviello G, D'Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N. Advances in anti-BRAF therapies for lung cancer. Invest New Drugs 2021;39:879-90. [PMID: 33474634 DOI: 10.1007/s10637-021-01068-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
132 Berge EM, Aisner DL, Doebele RC. Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR. J Thorac Oncol 2013;8:e83-4. [PMID: 23945392 DOI: 10.1097/JTO.0b013e31829ceb8d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
133 Liam CK, Poh ME, Liam YS. Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation. J Thorac Dis 2019;11:S1847-51. [PMID: 31632766 DOI: 10.21037/jtd.2019.08.117] [Reference Citation Analysis]
134 Improta G, Pettinato A, Gieri S, Scandurra G, Skovrider-Ruminski W, Høgdall E, Fraggetta F. Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. Oncol Lett 2016;11:393-8. [PMID: 26870223 DOI: 10.3892/ol.2015.3863] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
135 Chen D, Song Z, Cheng G. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther 2016;9:4181-6. [PMID: 27468240 DOI: 10.2147/OTT.S108242] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
136 Campelo RG, Massuti B, Mosquera J, Rosell R. 10(th) Congress on Lung Cancer-updates on clinical trials: goal. Transl Lung Cancer Res 2014;3:66-9. [PMID: 25806282 DOI: 10.3978/j.issn.2218-6751.2014.02.05] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Zhang Y, Wang Z, Hao X, Hu X, Wang H, Wang Y, Ying J. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations. Chin J Cancer Res 2017;29:18-24. [PMID: 28373750 DOI: 10.21147/j.issn.1000-9604.2017.01.03] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
138 Mansuet-Lupo A, Zouiti F, Alifano M, Tallet A, Charpentier MC, Ducruit V, Devez F, Lemaitre F, Laurent-Puig P, Damotte D, Blons H. Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis? J Transl Med 2014;12:131. [PMID: 24885034 DOI: 10.1186/1479-5876-12-131] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
139 Araki T, Yashima H, Shimizu K, Aomori T, Hashita T, Kaira K, Nakamura T, Yamamoto K. Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insights Oncol 2012;6:407-21. [PMID: 23239933 DOI: 10.4137/CMO.S7340] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
140 Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO Clin Res Rep 2021;2:100107. [PMID: 34589972 DOI: 10.1016/j.jtocrr.2020.100107] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Zhang B, Chen Y, Dai P, Yu H, Ma J, Chen C, Zhang Y, Guan Y, Chen R, Liu T, Wang J, Yang L, Yi X, Xia X, Ma H. Oncogenic mutations within the β3-αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies. Mol Genet Genomic Med 2020;8:e1395. [PMID: 32757330 DOI: 10.1002/mgg3.1395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
142 Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Tsai J, Vaks J, Current R, Lawrence HJ, Gonzalez de Castro D. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol 2013;66:381-5. [PMID: 23386666 DOI: 10.1136/jclinpath-2012-201240] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
143 Cai Y, Wang X, Guo Y, Sun C, Xu Y, Qiu S, Ma K. Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report. Medicine (Baltimore) 2019;98:e13890. [PMID: 30608413 DOI: 10.1097/MD.0000000000013890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
144 Cai Y, Wang Y, Sun J, Wang X, Xu Y, Sun C, Guo Y, Sun M, Ma K. Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report. J Int Med Res 2020;48:300060520928793. [PMID: 32493093 DOI: 10.1177/0300060520928793] [Reference Citation Analysis]
145 Shi J, Yang H, Jiang T, Li X, Zhao C, Zhang L, Zhao S, Liu X, Jia Y, Wang Y, Xi L, Zhang S, Su C, Ren S, Zhou C. Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. Chin J Cancer Res 2017;29:543-52. [PMID: 29353977 DOI: 10.21147/j.issn.1000-9604.2017.06.09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
146 Li HS, Zhang JY, Yan X, Xu HY, Hao XZ, Xing PY, Wang Y. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations. Cancer Med 2022. [PMID: 35023313 DOI: 10.1002/cam4.4495] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Yu X, Zhang X, Zhang Z, Lin Y, Wen Y, Chen Y, Wang W, Zhang L. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience. Cancer Commun (Lond) 2018;38:51. [PMID: 30055651 DOI: 10.1186/s40880-018-0321-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
148 Li H, Yang G, Cai Y, Li J, Xu H, Zhang T, Zhou L, Wang Y, Wang J, Hu X, Yan X, Wang Y. Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China. Front Pharmacol 2022;13:919652. [DOI: 10.3389/fphar.2022.919652] [Reference Citation Analysis]
149 Zhang L, Yang X, Ming Z, Shi J, Lv X, Li W, Yuan B, Che Y, Liu B, Qin K, Liu J, Wei Q, Gu D, Chen R, Yuan M, Cui J, Ou SI, Yang S. Molecular characteristics of the uncommon EGFR exon 21 T854A mutation and response to osimertinib in patients with non-small cell lung cancer. Clinical Lung Cancer 2021. [DOI: 10.1016/j.cllc.2021.12.008] [Reference Citation Analysis]
150 Van Acker L, Stevens D, Vermaelen K, Surmont V. Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report. J Med Case Rep 2021;15:562. [PMID: 34809713 DOI: 10.1186/s13256-021-02994-0] [Reference Citation Analysis]
151 Fang S, Wang Z. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Devel Ther 2014;8:1595-611. [PMID: 25302015 DOI: 10.2147/DDDT.S69690] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
152 Kim EY, Cho EN, Park HS, Hong JY, Lim S, Youn JP, Hwang SY, Chang YS. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther 2016;17:237-45. [PMID: 26785607 DOI: 10.1080/15384047.2016.1139235] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
153 Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I, De Pas T, Santoro A, Chella A, Brandes AA, Venturino P, Cuccurullo F, Crinò L, Buttitta F. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One 2014;9:e103883. [PMID: 25137181 DOI: 10.1371/journal.pone.0103883] [Cited by in Crossref: 92] [Cited by in F6Publishing: 101] [Article Influence: 11.5] [Reference Citation Analysis]
154 Jin LL, Wu ZZ, Wang YL, Chen DS, Li S, Xiao M, Zhao X. Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation. Invest New Drugs 2021. [PMID: 33835358 DOI: 10.1007/s10637-021-01108-3] [Reference Citation Analysis]
155 Koopman B, Cajiao Garcia BN, Kuijpers CCHJ, Damhuis RAM, van der Wekken AJ, Groen HJM, Schuuring E, Willems SM, van Kempen LC. A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses. Cancers (Basel) 2021;13:3641. [PMID: 34298851 DOI: 10.3390/cancers13143641] [Reference Citation Analysis]
156 Han L, Zhang X, Wang Z, Zhang X, Zhao L, Fu W, Liang X, Zhang Z, Wang Y. SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer. Front Pharmacol 2021;12:665253. [PMID: 33986687 DOI: 10.3389/fphar.2021.665253] [Reference Citation Analysis]
157 Masykura N, Zaini J, Syahruddin E, Andarini SL, Hudoyo A, Yasril R, Ridwanuloh A, Hidajat H, Nurwidya F, Utomo A. Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients. Lung Cancer (Auckl) 2019;10:57-66. [PMID: 31354372 DOI: 10.2147/LCTT.S180692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
158 Furuyama K, Harada T, Iwama E, Shiraishi Y, Okamura K, Ijichi K, Fujii A, Ota K, Wang S, Li H, Takayama K, Giaccone G, Nakanishi Y. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci 2013;104:584-9. [PMID: 23387505 DOI: 10.1111/cas.12125] [Cited by in Crossref: 29] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
159 Hellmann MD, Hayashi T, Reva B, Yu HA, Riely GJ, Adusumilli PS, Travis WD, Wilkins O, Bramletta N, Chandramohan R, Fleischut MH, Kris MG, Robson ME, Arcila ME, Paik PK, Ladanyi M. Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. JCO Precis Oncol 2017;1:PO. [PMID: 32913967 DOI: 10.1200/PO.16.00019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
160 Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Oncotarget 2016;7:36311-20. [PMID: 27121209 DOI: 10.18632/oncotarget.8904] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
161 Kuiper JL, Hashemi SM, Thunnissen E, Snijders PJ, Grünberg K, Bloemena E, Sie D, Postmus PE, Heideman DA, Smit EF. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer 2016;115:1504-12. [PMID: 27875527 DOI: 10.1038/bjc.2016.372] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
162 Huang JX, Wu YC, Cheng YY, Wang CL, Yu CJ. IRF1 Negatively Regulates Oncogenic KPNA2 Expression Under Growth Stimulation and Hypoxia in Lung Cancer Cells. Onco Targets Ther 2019;12:11475-86. [PMID: 31920336 DOI: 10.2147/OTT.S221832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol 2020;9:7. [PMID: 32337094 DOI: 10.1186/s40164-020-00159-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
164 Costa DB. Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. Transl Lung Cancer Res 2016;5:331-7. [PMID: 27413714 DOI: 10.21037/tlcr.2016.06.04] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
165 Wang Q, Mou J, Yang X, He Y, Li Z, Luo Q, Li Y, Lin L, Ma Y, Xiao H. EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers? Lung Cancer (Auckl) 2013;4:27-33. [PMID: 28210132 DOI: 10.2147/LCTT.S44825] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
166 Kim JS, Cho MS, Nam JH, Kim HJ, Choi KW, Ryu JS. Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer. PLoS One 2017;12:e0177015. [PMID: 28486527 DOI: 10.1371/journal.pone.0177015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
167 Blanc-Durand F, Florescu M, Tehfe M, Routy B, Alameddine R, Tran-Thanh D, Blais N. Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation. Curr Oncol 2021;28:1045-55. [PMID: 33652831 DOI: 10.3390/curroncol28020102] [Reference Citation Analysis]
168 Du W, Wo Y, Lu T, Wang Y, Jiao W. [A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer
with Uncommon EGFR Mutations]. Zhongguo Fei Ai Za Zhi 2019;22:590-9. [PMID: 31526464 DOI: 10.3779/j.issn.1009-3419.2019.09.07] [Reference Citation Analysis]
169 Yamamoto G, Kikuchi M, Kobayashi S, Arai Y, Fujiyoshi K, Wakatsuki T, Kakuta M, Yamane Y, Iijima Y, Mizutani H, Nakajima Y, Sudo J, Kinoshita H, Kurimoto F, Akiyama H, Uramoto H, Sakai H, Akagi Y, Akagi K. Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing. Int J Oncol 2017;50:1579-89. [PMID: 28350094 DOI: 10.3892/ijo.2017.3935] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
170 Li M, Zhou CZ, Yang JJ, Lu S, Zheng D, Hu J, Zeng H, Lu Y, Lu KH, Li SA, Mao XR, Han-Zhang H, Lizaso A, Ye JY, Hu CP. The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients.Cancer Biol Ther. 2019;20:1097-1104. [PMID: 30990107 DOI: 10.1080/15384047.2019.1595280] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
171 Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis. 2013;5 Suppl 5:S479-S490. [PMID: 24163741 DOI: 10.3978/j.issn.2072-1439.2013.08.03] [Cited by in F6Publishing: 104] [Reference Citation Analysis]
172 Kanaji N, Bandoh S, Hayashi T, Haba R, Watanabe N, Ishii T, Kunitomo A, Takahama T, Tadokoro A, Imataki O, Dobashi H, Matsunaga T. EGFR mutation identifies distant squamous cell carcinoma as metastasis from lung adenocarcinoma. World J Respirol 2013; 3(2): 38-43 [DOI: 10.5320/wjr.v3.i2.38] [Reference Citation Analysis]
173 Liu H, Zhang B, Sun Z. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun (Lond) 2020;40:43-59. [PMID: 32067422 DOI: 10.1002/cac2.12005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
174 Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, Sørensen JB. Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers (Basel) 2019;11:E923. [PMID: 31266248 DOI: 10.3390/cancers11070923] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
175 Takeda M, Sakai K, Hayashi H, Tanaka K, Tanizaki J, Takahama T, Haratani K, Nishio K, Nakagawa K. Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2. Oncotarget 2018;9:21132-40. [PMID: 29765525 DOI: 10.18632/oncotarget.24958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
176 Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389-1400. [PMID: 24202392 DOI: 10.1038/nm.3388] [Cited by in Crossref: 580] [Cited by in F6Publishing: 550] [Article Influence: 64.4] [Reference Citation Analysis]
177 Li M, Li M, Xie Y, Guo J. Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations. Molecules 2022;27:3844. [PMID: 35744964 DOI: 10.3390/molecules27123844] [Reference Citation Analysis]
178 Gou LY, Wu YL. Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China. Lung Cancer (Auckl). 2014;5:1-9. [PMID: 28210137 DOI: 10.2147/lctt.s40817] [Cited by in Crossref: 7] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
179 Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8:45-51. [PMID: 23242437 DOI: 10.1097/JTO.0b013e3182781e35] [Cited by in Crossref: 85] [Cited by in F6Publishing: 57] [Article Influence: 9.4] [Reference Citation Analysis]
180 Peng L, Song Z, Jiao S. Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation. Onco Targets Ther 2015;8:905-10. [PMID: 25960661 DOI: 10.2147/OTT.S78984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
181 Kang HJ, Hwangbo B, Lee JS, Kim MS, Lee JM, Lee GK. Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer. PLoS One. 2016;11:e0163652. [PMID: 27685950 DOI: 10.1371/journal.pone.0163652] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
182 Wei Y, Cui Y, Guo Y, Li L, Zeng L. A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review. Front Oncol 2021;11:700345. [PMID: 34178699 DOI: 10.3389/fonc.2021.700345] [Reference Citation Analysis]
183 D'Arcangelo M, Hirsch FR. Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics 2014;8:183-92. [PMID: 24790411 DOI: 10.2147/BTT.S40567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
184 Cushman-Vokoun AM, Crowley AM, Rapp SA, Greiner TC. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer. Am J Clin Pathol 2013;140:7-19. [PMID: 23765529 DOI: 10.1309/AJCPMF26ABEOYCHZ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
185 Watanabe M, Oizumi S, Kiuchi S, Yamada N, Yokouchi H, Fukumoto S, Harada M. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations. Intern Med 2018;57:993-6. [PMID: 29225262 DOI: 10.2169/internalmedicine.9565-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
186 Improta G, Zupa A, Natalicchio MI, Sisinni L, Marinaccio A, Bozza G, Vita G, Aieta M, Landriscina M. Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. Med Oncol 2018;35:28. [PMID: 29387949 DOI: 10.1007/s12032-018-1078-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
187 Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M; Afatinib Compassionate Use Consortium (ACUC). Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Oncologist 2015;20:1167-74. [PMID: 26354527 DOI: 10.1634/theoncologist.2015-0073] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
188 Ricciuti B, Baglivo S, Paglialunga L, De Giglio A, Bellezza G, Chiari R, Crinò L, Metro G. Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther Adv Med Oncol 2017;9:387-404. [PMID: 28607578 DOI: 10.1177/1758834017702820] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
189 Oxnard GR, Jänne PA. Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes. Clin Cancer Res 2013;19:1634-6. [PMID: 23403632 DOI: 10.1158/1078-0432.CCR-13-0169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
190 Suda K, Mitsudomi T. Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond. Lung Cancer (Auckl) 2013;4:43-53. [PMID: 28210134 DOI: 10.2147/LCTT.S49603] [Reference Citation Analysis]
191 Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, Zhang S, Jing W, Ma J, Han C. Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review. Front Oncol 2020;10:610923. [PMID: 33363040 DOI: 10.3389/fonc.2020.610923] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
192 Riely GJ, Yu HA. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clin Cancer Res 2015;21:2221-6. [PMID: 25979928 DOI: 10.1158/1078-0432.CCR-14-3154] [Cited by in Crossref: 46] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
193 Shi Y, Li P, Li B, Zhang F, Huang S, Shen S, Li X. [Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them]. Zhongguo Fei Ai Za Zhi 2019;22:299-305. [PMID: 31109439 DOI: 10.3779/j.issn.1009-3419.2019.05.06] [Reference Citation Analysis]
194 Chantharasamee J, Poungvarin N, Danchaivijitr P, Techawatanawanna S. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation. BMC Cancer 2019;19:701. [PMID: 31315599 DOI: 10.1186/s12885-019-5913-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
195 Tseng JS, Wang CL, Huang MS, Chen CY, Chang CY, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Wu CW, Yang CT, Chen YM, Chang GC. Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma. PLoS One 2014;9:e107160. [PMID: 25215536 DOI: 10.1371/journal.pone.0107160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
196 Xing K, Zhou X, Zhao X, Sun S, Luo Z, Wang H, Yu H, Wang J, Chang J, Wu X, Hu A. A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib. Med Oncol 2014;31:36. [PMID: 24908064 DOI: 10.1007/s12032-014-0036-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
197 Wang M, Ren D, Guo C, Ding X, Wang H. [Clinical Features of EGFR Double Mutation in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2018;21:594-9. [PMID: 30172266 DOI: 10.3779/j.issn.1009-3419.2018.08.05] [Reference Citation Analysis]
198 Hung YP, Chirieac LR. How should molecular findings be integrated in the classification for lung cancer? Transl Lung Cancer Res 2020;9:2245-54. [PMID: 33209647 DOI: 10.21037/tlcr-20-153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Xu Q, Zhu Y, Bai Y, Wei X, Zheng X, Mao M, Zheng G. Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction. Onco Targets Ther 2015;8:1533-41. [PMID: 26124670 DOI: 10.2147/OTT.S84938] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
200 Lei L, Wang WX, Zhu YC, Li JL, Fang Y, Wang H, Zhuang W, Zhang YB, Wang LP, Fang MY, Xu CW, Wang XJ, Lv TF, Song Y. Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study. Cancer Sci 2020;111:679-86. [PMID: 31828849 DOI: 10.1111/cas.14277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]